
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
FDA is juggling momentous changes, including new leadership and the proposed transfer of oversight for therapeutic biotech drugs.
about 24 years ago
Contract Servicesabout 24 years ago
Residual Solvent Analysis in Pharmaceuticals




